EnBiotix

EnBiotix is a clinical-stage rare disease company initially focused on chronic respiratory conditions, with a global market estimated at $15 billion. The initial programs target cystic fibrosis, non-CF bronchiectasis, and nontuberculous mycobacterial (NTM) lung disease. EnBiotix is building a rare disease pipeline through a combination of internal programs, corporate partnerships, and strategic acquisitions.